Clinical Trials · NCT05765500
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 110
- Start date
- Feb 2024
- Locations
- 3 sites, United States
- Primary endpoint
- 9-month Quality of Life (QOL) Score